Lymphedema Prevention Post Breast Cancer | LeaN On Study Australia
Discover how Flinders University's LeaN On study offers new hope for breast cancer survivors at risk of lymphedema through a digital self-management platform.
No reviews yet. Be the first to rate Neil!
Professor Neil Piller is a Lymphologist and Director of the Lymphoedema Clinical Research Unit in the College of Medicine and Public Health at Flinders University. He holds academic status as Web Supervisor and has served as the initial coordinator of the Advanced Studies Stream in the MD Program and as initial co-ordinator of year 2 of the MD program. His qualifications include a B.Sc (1972) and B.Sc (Hons) (1973) from the University of Adelaide, a Ph.D. (1979) from the University of Adelaide on the mode of action of benzopyrones in thermal and other oedemas, and FACP Emeritus status (2011).
Professor Piller’s research focuses on lymphoedema, including objective assessment, differential diagnosis, treatment sequencing, patient management strategies, and the impact of climate on chronic oedemas. He has held numerous leadership roles, including Patron of the Lymphoedema Association of Australia, executive member of the International Society for Lymphology, chief editor of the Journal of Lymphoedema, Australasian editor of the Journal of Lymphatic Research and Biology, and member of editorial boards for Phlebology and Lymphology. He has received awards such as the Pioneer Life Membership of the Australian Lymphology Association (2024), the Australasian Lymphology Association Lifetime Contribution Award (2016), and the Gold Medal for Advancement of Lymphoedema Research from the Australasian College of Phlebology (2011). Professor Piller has contributed to scientific and organising committees for international congresses and serves on advisory groups including ENCORE Australia and the SA Health Compression Advisory Group. His professional email address is publicly listed on the Flinders University staff profile.
Discover how Flinders University's LeaN On study offers new hope for breast cancer survivors at risk of lymphedema through a digital self-management platform.